Literature DB >> 33506982

Drug-induced peripheral oedema: An aetiology-based review.

Bérenger Largeau1, Jean-Luc Cracowski2, Céline Lengellé1, Bénédicte Sautenet3,4, Annie-Pierre Jonville-Béra1,4.   

Abstract

Many drugs are responsible, through different mechanisms, for peripheral oedema. Severity is highly variable, ranging from slight oedema of the lower limbs to anasarca pictures as in the capillary leak syndrome. Although most often noninflammatory and bilateral, some drugs are associated with peripheral oedema that is readily erythematous (eg, pemetrexed) or unilateral (eg, sirolimus). Thus, drug-induced peripheral oedema is underrecognized and misdiagnosed, frequently leading to a prescribing cascade. Four main mechanisms are involved, namely precapillary arteriolar vasodilation (vasodilatory oedema), sodium/water retention (renal oedema), lymphatic insufficiency (lymphedema) and increased capillary permeability (permeability oedema). The underlying mechanism has significant impact on treatment efficacy. The purpose of this review is to provide a comprehensive analysis of the main causative drugs by illustrating each pathophysiological mechanism and their management through an example of a drug.
© 2021 British Pharmacological Society.

Entities:  

Keywords:  capillary permeability; lymphedema; microcirculation; oedema; pharmacovigilance; renal reabsorption

Year:  2021        PMID: 33506982     DOI: 10.1111/bcp.14752

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Peripheral edema: A common and persistent health problem for older Americans.

Authors:  Soroush Besharat; Hanna Grol-Prokopczyk; Shan Gao; Changyong Feng; Frank Akwaa; Jennifer S Gewandter
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

Review 2.  Clinical Perspectives and Management of Edema in Chronic Venous Disease-What about Ruscus?

Authors:  Imre Bihari; Jean-Jérôme Guex; Arkadiusz Jawien; Gyozo Szolnoky
Journal:  Medicines (Basel)       Date:  2022-07-25

3.  Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors.

Authors:  Makoto Nishio; Terufumi Kato; Ryo Toyozawa; Toyoaki Hida
Journal:  Target Oncol       Date:  2022-09-10       Impact factor: 4.864

4.  Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.

Authors:  Kei Kunimasa; Takahisa Kawamura; Motohiro Tamiya; Takako Inoue; Hanako Kuhara; Kazumi Nishino; Toru Kumagai
Journal:  Thorac Cancer       Date:  2021-10-25       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.